Novartis DRC (NVSm)

Currency in ARS
66,675.00
-700.00(-1.04%)
Closed·
Advertisement
NVSm is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
66,675.0067,250.00
52 wk Range
45,980.0069,800.00
Key Statistics
Bid/Ask
65,100.00 / 83,250.00
Prev. Close
66,675
Open
66,800
Day's Range
66,675-67,250
52 wk Range
45,980-69,800
Volume
29
Average Volume (3m)
622
1-Year Change
41.3804%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NVSm Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 30 consecutive years

Novartis DRC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy

Earnings

Latest Release
27/10/2026
EPS / Forecast
0.63 / --
Revenue / Forecast
15.03B / --
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 8,026
Dividend Yield
1.46%
Industry Median 1.81%
Annualised payout
988.41
Paid annually
5-Years Growth
+6.59%
Growth Streak

Compare NVSm to Peers and Sector

Metrics to compare
NVSm
Peers
Sector
Relationship
P/E Ratio
29.4x34.2x−0.2x
PEG Ratio
−1.041.620.00
Price/Book
7.9x5.7x2.6x
Price / LTM Sales
5.1x4.8x2.7x
Upside (Analyst Target)
-3.1%68.5%
Fair Value Upside
Unlock2.1%11.5%Unlock

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Employees
75267
Market
Argentina

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
714.86M37.85%48.24T
Other Institutional Investors
161.84M8.57%10.92T
Public Companies & Retail Investors
1.01B53.58%68.28T
Total
1.89B100.00%127.43T

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.7.69%145,227,6509,799,235,684
UBS Asset Management AG4.87%92,060,2146,211,762,940

People Also Watch

120,725.000
AMATm
+2.35%
41.36
GS
-0.46%
5,225.00
ACNm
-3.24%
6,470.00
LRCXm
+2.45%

FAQ

What Is the Novartis DRC (Buenos Aires: NVSm) Share Price Today?

The Novartis DRC stock price today is 66,675.00 ARS.

What Stock Exchange Does Novartis DRC (NVSm) Trade On?

Novartis DRC is listed and trades on the Buenos Aires Stock Exchange.

What Is the Ticker (Stock Symbol) for Novartis DRC?

The stock symbol (also called a 'ticker') for Novartis DRC is "NVSm."

Does Novartis DRC Pay Dividends? What’s The Current NVSm Dividend Yield?

Yes, NVSm Pays Dividends to its Shareholders. The current Novartis DRC dividend yield is 1.5%%.

What Is the Current Novartis DRC Market Capitalisation?

As of today, Novartis DRC (Buenos Aires: NVSm) market cap is 459.51T ARS.

What Is Novartis DRC's (NVSm) Earnings Per Share (TTM)?

The Novartis DRC EPS is currently 8,026 (Trailing Twelve Months).

Is NVSm a Buy or Sell From a Technical Analyst Perspective?

Based on today's Novartis DRC moving averages and other technical indicators, the daily buy/sell signal for NVSm stock is Buy.

How Many Times Has Novartis DRC Stock Split?

Novartis DRC has split 1 times. (See the NVSm stock split history page for full effective split date and price information.)

How Many Employees Does Novartis DRC Have?

Novartis DRC has 75267 employees, based on their latest Companies House report.

What is the current trading status of Novartis DRC (Buenos Aires: NVSm)?

As of 19/11/2026, Novartis DRC (NVSm) is trading at a share price of 66,675.00 ARS, with a previous close of 66,675.00 ARS. The stock has fluctuated within a day range of 66,675.00 ARS to 67,250.00 ARS, while its 52-week range spans from 45,980.00 ARS to 69,800.00 ARS.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.